Starch-Based Fast-Dissolving Oral Vaccine Dosage Form

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing oral vaccine delivery methods face challenges in effectively stimulating mucosal immunity due to degradation in the gastrointestinal tract and poor absorption of antigens, leading to inadequate immune responses, and there is a need for improved solid oral dosage forms that can induce immune responses as effectively as injectable vaccines while being easy to administer and manufacture.

Innovation Solution

A fast-dissolving oral solid vaccine dosage form comprising an immunogenic amount of an antigenic preparation, a starch as an immune response potentiating matrix forming agent, and optional additional matrix forming agents like mannitol and gelatin, which facilitates rapid antigen uptake in the oral cavity, avoiding gastrointestinal degradation and enhancing both humoral and cell-mediated immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional tablets are used for oral vaccine delivery, then manufacturing is simple, but antigen absorption is poor and immune response is inadequate

Engineering Contradiction:
Improveimmune response effectivenessVSAvoiddosage form complexity
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the physical and chemical parameters of the dosage form by using freeze-drying to create a porous, fast-dissolving structure with specific surface area and porosity characteristics. This transforms the conventional dense tablet into a highly porous matrix that rapidly dissolves in oral fluids, exposing antigens to mucosal surfaces and significantly improving immune response effectiveness while maintaining manufacturing feasibility through established freeze-drying technology

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by combining the antigen with a porous matrix forming agent (such as gelatin, dextrin, or starch) and optionally with adjuvants and stabilizers. This composite structure provides both the mechanical integrity needed for handling and the rapid dissolution properties needed for effective mucosal delivery, resolving the contradiction between manufacturing simplicity and immune response effectiveness

Inventive Principle:
Principle #40Composite materials

2Ease of operation

If injectable vaccines are used, then immune response is effective, but administration is traumatic and inconvenient

Engineering Contradiction:
Improveadministration convenienceVSAvoidimmune response effectiveness
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent replaces the mechanical injection system with an oral delivery system that utilizes the natural physiology of the oral cavity. The fast-dissolving dosage form dissolves in oral fluids and delivers antigens directly to mucosal surfaces through passive dissolution and diffusion, eliminating the need for needles and injection equipment while maintaining immunogenicity by targeting the same mucosal-associated lymphoid tissues that injectable vaccines reach

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The porous fast-dissolving matrix acts as an intermediary carrier that protects the antigen during oral administration and facilitates its transfer to mucosal surfaces. The matrix forming agent (gelatin, dextrin, starch) serves as a biocompatible intermediary that dissolves rapidly in oral fluids, releasing the antigen in a controlled manner directly at the absorption site, thereby achieving injectable-level effectiveness through an oral route

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of operation

If oral vaccine is delivered through gastrointestinal tract, then administration is easy, but antigen degradation occurs and absorption is poor

Engineering Contradiction:
Improveoral administration easeVSAvoidgastrointestinal degradation
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by designing the dosage form to dissolve and release antigens in the oral cavity before the antigen enters the gastrointestinal tract. The fast-dissolving matrix releases antigens at the protected site of the oral mucosa, allowing absorption through mucosal surfaces before exposure to the harsh gastrointestinal environment with its degradative enzymes and acidic conditions, thereby preserving antigen integrity and enhancing absorption

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The starch-based formulation achieves improved immune responses by facilitating antigen uptake and absorption, inducing both systemic and mucosal immunity without the need for potent adjuvants, making it effective against a range of infectious agents and providing long-lasting protection.

Implementation Method 1

fast-dissolving oral solid vaccine dosage form comprising an immunogenic amount of an antigenic preparation, a starch as an immune response potentiating matrix forming agent

Methodology Applied
Scientific EffectCapillary action: Capillary Action

Implementation Method 2

facilitates rapid antigen uptake in the oral cavity

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 3

FDDFs manufactured by the freeze-drying process such as the Zydis® dosage form

Methodology Applied
Scientific EffectFreeze-drying: Freeze Drying

Data Source

PatentEP3095441B1Oral vaccine fast-dissolving dosage form using starch
Publication Date: 2020.12.02 R P SCHERER TECH INC
  • EP3095441B1 patent drawingFigure 1
  • EP3095441B1 patent drawingFigure 2~3
  • EP3095441B1 patent drawingFigure 4~5

AI summary

A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof.